IDEAS home Printed from https://ideas.repec.org/p/ohe/sembri/000074.html
   My bibliography  Save this paper

Can the US Afford to Ignore Cost-effectiveness Evidence?

Author

Listed:
  • James Chambers

Abstract

Cost-effectiveness analysis plays a limited role in US health care compared to many other countries. In this Seminar Briefing, Dr James Chambers, Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, considers the current use of cost-effectiveness analysis in the US and explores the potential value of including it in decisions about coverage for medical technology by Medicare (the national public health insurance programme primarily for people 65+ years of age). He reviews the current barriers in the US – both legislative and otherwise – to wider adoption of cost-effectiveness as a basis for health care decisions and notes attempts to use payment reform instead to increase incentives for greater efficiency.

Suggested Citation

  • James Chambers, 2014. "Can the US Afford to Ignore Cost-effectiveness Evidence?," Seminar Briefing 000074, Office of Health Economics.
    • Handle: RePEc:ohe:sembri:000074
    as

    Download full text from publisher

    File URL: https://www.ohe.org/publications/can-us-afford-ignore-cost-effectiveness-evidence/attachment-395-can-the-us-afford-to-ignore-ce-chambers-2014/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jorge Mestre-Ferrandiz;Patricia Deverka;Michele Pistollato;Emily Rosenberg, 2014. "The Current Drug Development Paradigm: Responding to US and European Demands for Evidence of Comparative Effectiveness and Relative Effectiveness," Occasional Paper 000076, Office of Health Economics.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Petra Marešová & Lukáš Peter & Jan Honegr & Lukáš Režný & Marek Penhaker & Martin Augustýnek & Hana Mohelská & Blanka Klímová & Kamil Kuča, 2020. "Complexity Stage Model of the Medical Device Development Based on Economic Evaluation—MedDee," Sustainability, MDPI, vol. 12(5), pages 1-27, February.
    2. John Vernon & Joseph Golec & J. Stevens, 2010. "Comparative Effectiveness Regulations and Pharmaceutical Innovation," PharmacoEconomics, Springer, vol. 28(10), pages 877-887, October.
    3. Gandjour, Afschin & Chernyak, Nadja, 2011. "A new prize system for drug innovation," Health Policy, Elsevier, vol. 102(2), pages 170-177.

    More about this item

    Keywords

    Can the US Afford to Ignore Cost-effectiveness Evidence?;

    JEL classification:

    • I1 - Health, Education, and Welfare - - Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:ohe:sembri:000074. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Publications Manager (email available below). General contact details of provider: https://edirc.repec.org/data/ohecouk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.